Combined Therapy with Renin-Angiotensin System and Calcium Channel Blockers in Type 2 Diabetic Hypertensive Patients with Proteinuria | Zendy

Mahmut İlker Yılmaz | Zendy; Juan Jesús Carrero | Zendy; José Luis Martı́n-Ventura | Zendy; Alper Sönmez | Zendy; Mutlu Sağlam | Zendy; Turgay Çelik | Zendy; Halıl Yaman | Zendy; Müjdat Yenicesu | Zendy; Tayfun Eyıleten | Zendy; Juan Antonio Moreno | Zendy; Jesús Egido | Zendy; Luis Miguel BlancoColio | Zendy

Open Access

Combined Therapy with Renin-Angiotensin System and Calcium Channel Blockers in Type 2 Diabetic Hypertensive Patients with Proteinuria

Author(s) -

Mahmut İlker Yılmaz,

Juan Jesús Carrero,

José Luis Martı́n-Ventura,

Alper Sönmez,

Mutlu Sağlam,

Turgay Çelik,

Halıl Yaman,

Müjdat Yenicesu,

Tayfun Eyıleten,

Juan Antonio Moreno,

Jesús Egido,

Luis Miguel BlancoColio

Publication year - 2010

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.01110210

Subject(s) - medicine , amlodipine , valsartan , ptx3 , proteinuria , combination therapy , kidney disease , olmesartan , renal function , urology , endocrinology , cardiology , pharmacology , blood pressure , kidney , inflammation

Soluble TNF-like weak inducer of apoptosis (sTWEAK) and long pentraxin-3 (PTX3) concentrations have been associated with endothelial function in patients with chronic kidney disease (CKD). This study tested the hypothesis that the improvement in endothelial function after initiation of angiotensin II receptor blocker (valsartan), calcium channel blocker (amlodipine) therapy, or a combination of both is directly linked to the normalization of sTWEAK and PTX3.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research